Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis

NCT03536559 is registered in ClinicalTrials.gov with Clene Nanomedicine as lead sponsor.

NCT NCT03536559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03536559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis
Lead sponsor
Clene Nanomedicine
Phase
Phase 2
Overall status
Terminated
Start date
November 23, 2018
Completion date
July 12, 2022
Enrollment
73 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

optic neuropathy, optic; neuritis, with demyelination, relapsing remitting multiple sclerosis